WO2000052479A3 - Diagnostics and therapeutics for drusen associated ocular disorders - Google Patents
Diagnostics and therapeutics for drusen associated ocular disorders Download PDFInfo
- Publication number
- WO2000052479A3 WO2000052479A3 PCT/US2000/005858 US0005858W WO0052479A3 WO 2000052479 A3 WO2000052479 A3 WO 2000052479A3 US 0005858 W US0005858 W US 0005858W WO 0052479 A3 WO0052479 A3 WO 0052479A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutics
- diagnostics
- ocular disorders
- associated ocular
- drusen associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33958/00A AU3395800A (en) | 1999-03-05 | 2000-03-06 | Diagnostics and therapeutics for drusen associated ocular disorders |
EP00912189A EP1161686A2 (en) | 1999-03-05 | 2000-03-06 | Diagnostics and therapeutics for drusen associated ocular disorders |
CA002363503A CA2363503C (en) | 1999-03-05 | 2000-03-06 | Diagnostics and therapeutics for drusen associated ocular disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12305299P | 1999-03-05 | 1999-03-05 | |
US60/123,052 | 1999-03-05 | ||
US51023000A | 2000-02-22 | 2000-02-22 | |
US09/510,230 | 2000-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000052479A2 WO2000052479A2 (en) | 2000-09-08 |
WO2000052479A3 true WO2000052479A3 (en) | 2001-02-01 |
Family
ID=26821176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/005858 WO2000052479A2 (en) | 1999-03-05 | 2000-03-06 | Diagnostics and therapeutics for drusen associated ocular disorders |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1161686A2 (en) |
AU (1) | AU3395800A (en) |
CA (1) | CA2363503C (en) |
WO (1) | WO2000052479A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9279148B2 (en) | 1999-04-20 | 2016-03-08 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
AU6110301A (en) | 2000-04-29 | 2001-11-12 | Univ Iowa Res Found | Diagnostics and therapeutics for macular degeneration-related disorders |
US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
US6986995B2 (en) * | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
EP2357254A1 (en) | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
US8088773B2 (en) * | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
CA2621953A1 (en) * | 2005-09-09 | 2007-03-22 | University Of Iowa Research Foundation | Biomarkers associated with age-related macular degeneration |
US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
KR20150032552A (en) | 2012-06-11 | 2015-03-26 | 매큐클리어 인코포레이션 | Therapeutic formulation and methods of treatment |
GB201306627D0 (en) * | 2013-04-11 | 2013-05-29 | Thompson Richard | Marker |
AU2014236782B2 (en) | 2013-03-14 | 2019-01-03 | Baxalta GmbH | Factor H for treatment of rheumatoid arthritis |
PT2968457T (en) | 2013-03-14 | 2018-11-07 | Baxalta Inc | Factor h for transplantation |
AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
US9423394B2 (en) * | 2013-12-13 | 2016-08-23 | TheraOptix, Inc. | Retinal pigment epithelial primary cell culture system producing subcellular deposits |
EP3504554B1 (en) | 2016-08-23 | 2024-04-03 | University of Maryland, Baltimore | Methods for detecting and/or predicting age-related macular degeneration and/or alzheimer's disease |
-
2000
- 2000-03-06 WO PCT/US2000/005858 patent/WO2000052479A2/en active Search and Examination
- 2000-03-06 AU AU33958/00A patent/AU3395800A/en not_active Abandoned
- 2000-03-06 EP EP00912189A patent/EP1161686A2/en not_active Withdrawn
- 2000-03-06 CA CA002363503A patent/CA2363503C/en not_active Expired - Fee Related
Non-Patent Citations (9)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9279148B2 (en) | 1999-04-20 | 2016-03-08 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
US9441267B2 (en) | 1999-04-20 | 2016-09-13 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
Also Published As
Publication number | Publication date |
---|---|
AU3395800A (en) | 2000-09-21 |
CA2363503C (en) | 2009-03-10 |
WO2000052479A2 (en) | 2000-09-08 |
EP1161686A2 (en) | 2001-12-12 |
CA2363503A1 (en) | 2000-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2407715A1 (en) | Diagnostics and therapeutics for macular degeneration-related disorders | |
WO2000052479A3 (en) | Diagnostics and therapeutics for drusen associated ocular disorders | |
AU2002366641A1 (en) | Methods for inhibiting ocular processes | |
HK1040266A1 (en) | Titanium alloy and method for producing the same. | |
AP2004003026A0 (en) | Methods for treating ocular neovascular diseases. | |
WO2003071927A3 (en) | Diagnostics and therapeutics for macular degeneration-related disorders | |
AU2002325835A1 (en) | Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles | |
MXPA03007983A (en) | Process for the preparation of middle distillates. | |
WO2001079461A3 (en) | Polypeptides having haloperoxidase activity | |
ZA993364B (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses. | |
ZA200309977B (en) | Arylamines for the treatment of conditions associated with GSK-3. | |
ZA200108854B (en) | Method for the preparation of citalopram. | |
HK1038007A1 (en) | Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. | |
WO2001097809A3 (en) | Method of treating cardiovascular disease using rapamycin | |
WO2001017543A3 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
WO2000020470A3 (en) | Aqueous dispersions | |
GC0000155A (en) | 6-Hydroxy-indazole derivatives for treating glaucoma. | |
HK1052702A1 (en) | Method for the preparation of 5-carboxyphthalide. | |
WO2001016377A3 (en) | Diagnostics and therapeutics for osteoporosis | |
AU3824599A (en) | Method for producing (s,s)-benzyl-2,8-diazabicyclo{4.3.0}nonane | |
ZA993852B (en) | Diaza-Spiro (3,5)nonane derivates. | |
MXPA03006607A (en) | Combined method for treating hormono-dependent disorders. | |
ZA997027B (en) | High-temperature, water-based lubricant and process for making the same. | |
WO2004045376A3 (en) | Screening methods to identify treatments for autoimmune disease | |
ZA200205098B (en) | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2363503 Country of ref document: CA Ref country code: CA Ref document number: 2363503 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 33958/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000912189 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000912189 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |